Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.70 |
| ▸ | JAK1 | P23458 | 20/20 | 0.70 |
| ▸ | TYK2 | P29597 | 2/20 | 0.66 |
| ▸ | JAK3 | P52333 | 2/20 | 0.66 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21280995 | 0.92 | JAK2 (0.76) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL11028339 | 0.91 | JAK2 (0.80) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL30052224 | 0.91 | JAK2 (0.69) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL11032419 | 0.91 | JAK2 (0.69) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL17282290 | 0.91 | JAK2 (0.69) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL18893991 | 0.90 | JAK2 (0.77) | JAK2JAK1 | |
| SCHEMBL20499824 | 0.90 | JAK2 (0.67) | JAK2JAK1 | |
| SCHEMBL20560540 | 0.90 | JAK2 (0.71) | JAK2JAK1 | |
| SCHEMBL18893881 | 0.90 | JAK2 (0.73) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL11028422 | 0.89 | JAK2 (0.69) | JAK2JAK1TYK2JAK3LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204517-A1 | INHALED POWDER FORMULATIONS | GENENTECH, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220024945-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024945-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20200165260-A1 | INHALED POWDER FORMULATIONS | GENENTECH, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200062779-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| US-20200062779-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| EP-3380474-B1 | JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-08-21 | — | — | EP | disclosed |
| US-20180334465-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-11-22 | — | — | US | disclosed |
| WO-2017089390-A1 | JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024945-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885TYK2 18/4885 |
| US-20200165260-A1 | INHALED POWDER FORMULATIONS | JAK1, STAT5A, JAK2 | JAK2 3/4885JAK1 1/4885TYK2 161/4885 |
| US-20200062779-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885TYK2 18/4885 |
| US-20220204517-A1 | INHALED POWDER FORMULATIONS | JAK1, STAT5A, JAK2 | JAK2 3/4885JAK1 1/4885TYK2 161/4885 |
| US-20180334465-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885TYK2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.